- Molecular NameTolterodine
- SynonymTolterodina [INN-Spanish]; Tolterodine [INN]; tolterodine extended release capsules; Tolterodine L-Tartrate; Tolterodine Tartrate; Tolterodinum [INN-Latin]; Tolterondine Tartrate
- Weight325.496
- Drugbank_IDDB01036
- ACS_NO124937-51-5
- Show 2D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)5.33
- pka9.9
- LogD (pH=7, predicted)3.05
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-1.55
- LogSw (predicted, AB/LogsW2.0)0.04
- Sw (mg/ml) (predicted, ACD/Labs)0.08
- No.of HBond Donors1
- No.of HBond Acceptors2
- No.of Rotatable Bonds7
- TPSA23.47
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn antimuscarinic drug that is used to treat urinary incontinence.
- Absorption_value77.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability26.0
- Protein binding96.3
- Volume of distribution (VD)1.7 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmTolterodine (T) is metabolized primarily by CYP2D6 to an active (100% potency) metabolite, 5-hydroxymethyl tolterodine (5-HM), in extensive metabolizers (EM). Also metabolized by CYP3A to an N-desalkyl product, particularly in poor metabolizers (PM).
- Half life2.3 h in extensive metabolisers; 9.2 in poor metabolisers.
- ExcretionN/A
- Urinary ExcretionNegligible
- Clerance9.6 ml/min/kg
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A